Controlled drug loading and release into tumor cells to increase the intracellular drug concentration is a major challenge for cancer therapy due to resistance and inefficient cellular uptake. Here, a temperature and pH dual responsive PNiPAM/AA@SiO 2 core-shell particles with internal controlled release were designed and fabricated for efficient cancer treatment, which could recognize the intrinsic pH differences between cancers and normal tissues. Upon lowering the temperature, doxorubicin was loaded into the PNiPAM/AA@SiO 2 nanoparticles, whereas by increasing the acidity, previously loaded doxorubicin was quickly released. Comparing with common mesoporous silica particles (MSNs), these core-shell particles have a more uniform size and better dispersity. In addition, dried PNiPAM/AA@SiO 2 nanoparticles could be easily redispersed in distilled water. The in vitro cell culture experiments showed that not only were PNiPAM/AA@SiO 2 particles more biocompatible and less cytotoxic than MSN, but also DOX@PNiPAM/AA@SiO 2 had a higher drug release efficiency in the lysosomes and a stronger inhibitory effect on tumor cell growth than DOX@MSN. All these features indicated that PNiPAM/ AA@SiO 2 particles have great potential in therapy applications.
Introduction
Recently, various nanostructured materials have been developed for biomedical imaging, diagnostics and therapy, because they show improved pharmacokinetics and biodistribution and exciting efficacy for cancer treatments. However, the poor cellular internalization of nanoparticles and insufficient intracellular drug release always limits the amount of anticancer drugs that actually reach cancer cells, which hampers the efficacy of cancer chemotherapy. To conquer the challenges, stimuli-responsive nanoparticles have been regarded as one of the most promising carriers for drug delivery, which are sensitive to environmental stimuli such as temperature, 1-4 ionic strength, 5 ultraviolet light, 6 or magnetic eld.
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It is well documented that pH values in different tissues and cellular compartments vary signicantly. For example, the tumor extracellular environment is more acidic (pH 6.8)
10 than blood and normal tissues (pH 7.4), and the pH values of late endosome and lysosome are even lower, at 5.0-5.5.
11 So a pH sensitive delivery system is of special interest for controlled drug delivery.
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Mesoporous silica nanoparticles have been extensively explored as drug delivery systems due to their superior features such as high pore volume, large surface area, prominent biocompatibility, accessible surface functionalization, and effective protection for the payloads. [15] [16] [17] [18] With the aim to administer drug molecules specically toward target tissues, pH sensitive molecules have been introduced to prepare hybrid nanoparticles with MSN. 19, 20 The pore surface and opening of MSNs have been functionalized with stimuliresponsive groups, [21] [22] [23] [24] inorganic nanoparticles, 25 and peptide 26 that worked as caps and gatekeepers. 15, 27 Controlled release of encapsulated drugs can be triggered in responding to internal or external stimuli such as pH, temperature, redox potential, light, and enzymatic reactions.
For example, the folate was linked by disulde bonds to construct the gate-like structure on the outlet of the pores of MSNPs, the controlled release can be triggered in the presence of reductant dithiothreitol or glutathione (GSH). 28 MSNP coated by PEG-DA-peptide macromer possessing MMP substrate polypeptides can be responsive to endogenous proteases triggered, localized drug release in vitro and in vivo. 29 Nanoparticles with pH responsive hydrazone bonds immobilized on a mesoporous silica nanocomposite allow pH-sensitive drug release. 30 Polyvalent mesoporous silica nanocarriers-aptamer bioconjugates were fabricated as controlled release drug delivery systems and were able to effectively target cancer cells.
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Despite the success of these approaches, they need to be improved because of the tedious multiple-step syntheses, necessity of suitable surfactants, very low surface graing efficiency or encapsulation efficiency, etc., and more importantly, slow release of the encapsulated drug and low releasing efficiency caused by strong adsorption of MSNP. Therefore, it is in our interest to explore a simple and facile method to prepare drug carriers that are capable of recognizing the intrinsic pH differences between tumor and normal tissues and possessing higher releasing efficiency and faster release behavior at low pH.
Herein, we propose a facile and efficient strategy to introduce the pH/thermo-responsive nanocarriers with dually responsive poly(N-isopropylacrylamide) (PNiPAM)-co-acrylic acid (AA) hydrogel core enclosed in silica shell via self-assembly approach. The PNiPAM/AA@silica particles not only possess pH/thermal responsive features, high dispersity and the unique features derived from a silica shell, but also have improved drug release efficiency in cells. The physicochemical and pH/thermosensitive properties of PNiPAM/AA@silica composite microspheres were tested. Doxorubicin hydrochloride (DOX), a classic anticancer drug, was chosen as a model drug to assess the drug loading and releasing behaviors of the carriers. The cytotoxicity of PNiPAM/AA@silica and DOX@PNiPAM/AA@silica to MCF-7 cells was measured. The drug release efficiency of DOX@PNi-PAM/AA@SiO 2 in cells had been compared with that of DOX@MSN.
Materials and methods

Materials
and trypsin were purchased from Sigma-Aldrich (St. Louis, USA). Lysotracker Green was purchased from Invitrogen. Acrylic acid (AA), sodium dodecyl sulfate (SDS) and ammonium persulfate (APS) were obtained from Shanghai Chemical Reagents Company (Shanghai, China). NiPAM was recrystallized from n-hexanes and dried under vacuum prior to use.
Synthesis of mesoporous silica nanoparticles
Mesoporous silica nanoparticles (MSNs) were synthesized as previously reported. [32] [33] [34] Briey, 200 mg of CTAB were dissolved in 96 mL of water, followed by the addition of 7 mL of 0.2 M NaOH aqueous solution. The solution was heated to 80 C and kept at that temperature for 30 minutes before 1 mL of TEOS was added. The solution went from clear to opaque, indicative of a hydrolysis process. The reaction was kept at 80 C for 2 h.
The resulting nanoparticles were centrifuged and washed with methanol. In order to remove the CTAB, the as-synthesized particles were suspended in 50 mL solution of methanol and 2.0 mL of 12 M hydrochloride acid. The solution was reuxed for 10 h and the MSNs were collected by centrifugation and washed with methanol.
Synthesis of PNiPAM/AA hydrogel nanoparticles
The PNiPAM/AA hydrogel particles were prepared by the precipitation polymerization of NiPAM, MBA and AA using APS as an initiator. More specically, an appropriate amount of NiPAM, AA and MBA was dissolved in 120 mL of doubly distilled water containing 0.042 g of SDS. The dispersion was purged with nitrogen for 30 min under continuous mechanical stirring at 500 rpm (revolutions per minute) at room temperature. Then the solution was heated to 70 C, and APS (0.053 g) dissolved in 3 mL of water was quickly injected to initiate the polymerization. The reaction mixture was stirred for 12 h at 70 C under the nitrogen atmosphere. The obtained PNiPAM/AA nanoparticles were centrifuged and thoroughly washed with water and methanol to remove SDS and unreacted monomers. [35] [36] [37] The puried PNiPAM/AA particles were redispersed in distilled water at a solid content of 0.5 wt% for subsequent use.
Synthesis of PNiPAM/AA@SiO 2 nanoparticles
The synthesis procedure was described as following: 10 mg of CTAB was dissolved in 5 mL of water, then a predetermined amount of above PNiPAM/AA particles and TEOS were added, and the mixture was ultrasonically treated for 30 minutes. Then the mixture was stirred at 37 C for 24 h. The obtained PNiPAM/ AA@SiO 2 nanoparticles were centrifuged and thoroughly washed with distilled water and then re-dispersed in water at a solid content of 1.0 wt% for further use.
Synthesis of FITC-PNiPAM/AA@SiO 2 nanoparticles
FITC-graing PNiPAM/AA@SiO 2 nanoparticles were prepared with modied Stöber method. 38 A typical synthesis procedure was depicted as following: 5 mg of uorescein isothiocyanate (FITC) was reacted with 25 mg 3-aminopropyl trimethoxysilane (APS) in 2 g absolute ethanol by stirring for 48 h at room temperature. Then 200 mL of the resulting solution was mixed with 200 mg PNiPAM/AA@SiO 2 and injected into the mixed solution of water (0.5 g) and ethanol (1.5 g). The mixed solution was magnetically stirred at room temperature for 48 h. The obtained particles were centrifugated and washed with ethanol and distilled water three times, respectively. The FITC-graing PNiPAM/AA@SiO 2 nanoparticles were nally redispersed in water.
Drug loading into SiO 2 and PNiPAM/AA@SiO 2 nanoparticles
Doxorubicin was dissolved in distilled water to prepare 3 mg mL À1 solutions. 1.5 mL of the doxorubicin solution was pipetted into test tubes containing 3 mL of 10 mg mL À1 SiO 2 or 3 mL of 10 mg mL À1 PNiPAM/AA@SiO 2 solution. The mixed solution was kept at 4
C for 24 h, to reach maximum doxorubicin loading. Then the dispersion was centrifuged at 6000 rpm for 10 min to separate the loaded nanoparticles and carefully washed with distilled water twice. The amount of drugs loaded in the nanoparticles was determined by subtracting the amount of drug in the supernatant from that in the loading solution using a UV spectrophotometer with the detection wavelength of 485 nm.
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In vitro drug release from the DOX@SiO 2 and DOX@PNiPAM/AA@SiO 2 nanoparticles
Nanoparticles loaded with doxorubicin were re-dispersed in 5 mL of PBS (pH 7.4 and 5.0) immediately aer loading. The dispersion was then transferred into a dialysis bag (molecular weight cut off 7000 Da) and the bag was subsequently placed in a 50 mL centrifuge tube containing 25 mL of PBS. 5 mL of solution was sampled from the tube every half an hour during the rst three hours, then sampled every hour in the following four hours. Finally, 5 mL of solution was taken out every day and the released drug was determined spectrophotometrically. The volume of the release medium in the ask was kept constant by adding equal volume of fresh medium back aer each sampling. All drug release data were averaged with three measurements.
Cell culture
Human breast cancer cells (MCF-7) and human embryonic kidney (HEK293, normal cell) cells were maintained in Dulbecco's modied Eagle's medium (DMEM) and Minimum Essential Medium (MEM) supplemented with 10% (v/v) fetal bovine serum (FBS) in a humidied atmosphere containing 5% CO 2 at 37 C.
The cytotoxicity assay
The cytotoxicity of DOX@PNiPAM/AA@SiO 2 against MCF-7 cells was determined by standard MTT assay. Briey, the cells were seeded onto 96-well plates at a density of 5000 viable cells per well and incubated for 24 h to allow cell attachment. Then the cells were incubated with free DOX, DOX@SiO 2 , DOX@PNi-PAM/AA@SiO 2 with the doxorubicin concentrations ranging from 0.08 to 20 mg mL À1 , and blank PNiPAM/AA@SiO 2 from 0.4 to 200 mg mL À1 respectively. Aer 48 h, fresh medium containing MTT (0.5 mg mL À1 ) were replaced and the cells were incubated for additional 3.5 h. Upon removing MTT solution, the purple formazan crystals were dissolved with 100 mL DMSO, and the absorbance was recorded at 570 nm with a microplate reader (TECAN Znnite M200, Austria). Untreated cells in medium were used as a control. Corresponding groups without cells were used as blanks. All experiments were carried out with four replicates. 
Confocal microscopy assay
General analysis
The average hydrodynamic radius of MSN, PNiPAM/AA and PNiPAM/AA@SiO 2 nanoparticles at different temperatures and pH were determined by ZetaSizer Nano ZS (Malvern Instruments Ltd., Worcestershire, UK). All the measurements were performed with the nanoparticles suspended in distilled water at the concentration of 100 mg mL
À1
. TEM images were obtained using a Tecnai G2 20 S-TWIN transmission electron microscope (FEI Company) operating at 200 kV. Samples were deposited onto carbon coated copper grids, dried at room temperature and stained with uranyl acetate when necessary.
Infrared spectroscopy was carried out using a Spectrum One FT-IR spectrometer. The freeze-dried nanoparticles were grounded with KBr and pressed into a thin wafer. For each sample, 32 scans were recorded from 4000 to 400 cm À1 with a resolution of 2 cm À1 .
Nitrogen adsorption-desorption isotherms were measured at À196
C by ASAP 2020 (M+C) (Micromeritics, America).
Before the samples were analyzed, they were degassed in a vacuum at 150 C for 12 hours. Specic surface area was calculated using the multiple-point Brunauer-Emmett-Teller method. Pore volume was determined from the adsorption branch of nitrogen adsorption-desorption isotherm curve at a relative nitrogen pressure P/P 0 ¼ 0.992 signal point. Pore diameter was calculated from the adsorption branch of the isotherms using the Barrett-Joyner-Halenda method.
3 Results and discussion
Synthesis physicochemical characterization of nanoparticles
In order to achieve an optimal controllable delivery system for doxorubicin, three types of particles (Mesoporous silica particles, PNiPAM/AA hydrogel particles and PNiPAM/AA@SiO 2 particles) were prepared. Mesoporous silica nanoparticles (MSNs) with highly ordered mesostructures and spherical morphology were synthesized, using CTAB as template. As shown in Fig. 1a , spherical particles of MSNs with regular morphology and diameter of approximately 100 nm were obtained. The mean particle size of MSNs in H 2 O determined by dynamic light scattering was about 525.8 nm, and the zeta potential was À29.1 mV ( Table 1 ). The 2D cylindrical pores with the diameter of 2-3 nm were arranged in parallel. Transmission electron microscopy (TEM) images of PNi-PAM/AA hydrogel nanoparticles and PNiPAM/AA@SiO 2 nanoparticles are shown in Fig. 1b stretching vibration. Two typical bands of C-H vibration at 1387.5 and 1367.5 cm À1 belong to the divided bands of the symmetric -CH(CH 3 ) 2 group. In the spectra of the NiPAM/ AA@SiO 2 , the typical peaks are similar to those of MSN and NiPAM/AA. These ndings indicate that NiPAM/AA@SiO 2 shellcore particles were successfully obtained.
Determination of dispersity and modication of PNiPAM/AA@SiO 2 nanoparticle powder
One of problems of various nanotherapeutic candidates is that particles tend to agglomerate. Good dispersity of therapeutic nanoparticles is essential. 41 Here, the dispersity of PNiPAM/ AA@SiO 2 nanoparticles was evaluated and compared with that of MSN. Nanoparticles of PNiPAM/AA and MSN in ethanolic suspensions were dried using rotary evaporation and redispersed in distilled water (Fig. 3a) . A well-suspended, optically transparent colloidal solution could be clearly seen aer simply redispersing the powder in distilled water by ultrasonication for 5 min. The hydrodynamic size of the redispersed PNiPAM/ AA@SiO 2 nanoparticles is $274 nm in distilled water and slightly larger than as-synthesized PNiPAM/AA@SiO 2 nanoparticles ($234 nm). As shown in Fig. 3b , PNiPAM/AA@SiO 2 nanoparticles have much better dispersity than MSN.
In order to determine whether the prepared PNiPAM/ AA@SiO 2 particles can be chemically modied similarly as MSN, FITC was graed to the SiO 2 shell of the particles and their hydrodynamic size was measured using DLS. The hydrodynamic size distribution of synthesized FITC-PNiPAM/ AA@SiO 2 particles was almost identical to the unmodied PNiPAM/AA@SiO 2 particles, as shown in Fig. 4a . Yellowish and transparent colloidal solutions showing Tyndall light scattering behavior further conrmed the dispersity of the FITC-PNiPAM/ AA@SiO 2 particles (Fig. 4b) . The uorescence of FITC-PNiPAM/ AA@SiO 2 particles under UV illumination was homogeneously distributed in water (Fig. 4c) .
The above results indicate that PNiPAM/AA@SiO 2 nanoparticles obtained by the simple self-assembly method have a relatively better dispersity than MSN, nevertheless their surface could be modied just like MSN.
Thermal sensitive characterization of PNiPAM/AA@SiO 2 particles
Here, we further study the inuence of temperature on the size of PNiPAM/AA@SiO 2 core-shell nanoparticles. As shown in Fig. 5 , the particles, prepared at 37 C, became slightly swollen when the temperature decreased from 47 C to 21 C. It is interesting that aer the particles were stored for 24 hours at room temperature, the size of the particles increased by about 10 nm, and the size of the nanoparticles went back to the original size when the medium temperature was raised again 37 C above. The reason for the size increment of the nanoparticles might be that the sustained expanding force of PNiPAM/AA cores at lower temperature for a long time acted on SiO 2 shells and the shells were broken open along the gap. When the temperature was raised, contraction force of the cores would draw the open shells back to original topography. According to the results, PNiPAM/AA@SiO 2 nanoparticles will expand and the drug could be loaded into the nanoparticles when the medium temperature decreases. Then the medium temperature is returned to its preparation temperature and the drug is encapsulated into the nanoparticles, as shown in Fig. 6 . In turn, the release of drug molecules from DOX@PNiPAM/ AA@SiO 2 was accelerated when the temperature was decreased (Fig. S1 †) .
Effect of pH values on drug release
In order to determine whether lower pH can trigger drug release at body temperature, PNiPAM/AA@SiO 2 nanoparticles were fabricated at 37 C and doxorubicin was loaded for 48 h at 4 C and neutral pH. Drug loading contents and encapsulating efficiency of MSN and PNiPAM/AA@SiO 2 nanoparticles are 9.98%, 71.59% and 5.98%, 51.89%, respectively. In vitro release proles Journal of Materials Chemistry B Paper of DOX from MSN, PNiPAM/AA and PNiPAM/AA@SiO 2 nanoparticles were examined in phosphate buffer at pH 7.4 and pH 5.0, respectively. As shown in Fig. 7 , the drug release rate of both particles was faster at low pH (pH 5.0) than at high pH (pH 7.4). There was a slight difference between the cumulative drug release from MSNs at pH 7.4 and pH 5.0, which was respectively about 50% and 67%. However, at pH 7.4 the amount of cumulative drug released from PNiPAM/AA@SiO 2 (about 20%) is signicantly lower than that of MSN and PNiPAM/AA particles (about 60%, Fig. 7b ). When the medium pH value was reduced to 5.0, the accumulated released drug from PNiPAM/AA@SiO 2 quickly improved to 80%. The results clearly show that PNiPAM/ AA@SiO 2 improved drug release efficiency in acidic medium and decreased the amount of cumulative drug released from PNiPAM/AA cores in neutral medium. The reason for the result is that the protons in the acidic buffer solution can easily get into the core through the gap of shell to protonate the amino group of DOX, which accelerate the drug release. This release behavior is desirable for cancer treatment, i.e. most of the drug remains encapsulated in the nanocarrier during circulation, but when it reaches the acidic tumor tissue, the low pH triggers drug release.
Cell viability assay
To evaluate the potential of PNiPAM@SiO 2 nanoparticles as effective drug carriers for cancer therapy, in vitro cytotoxicity of DOX@MSN and DOX@PNiPAM/AA on MCF-7 cells was investigated. MCF-7 cells were incubated with DOX@MSN and DOX@PNiPAM/AA@SiO 2 at equivalent doxorubicin doses for 48 h, respectively. As shown in Fig. 8a , signicant dose-dependent inhibition of MCF-7 cells' proliferation was observed when the Journal of Materials Chemistry B Paper cells were treated with DOX@PNiPAM/AA@SiO 2 , but DOX@MSN showed mild toxicity to MCF-7 cells. On the other hand, the blank carrier of PNiPAM/AA@SiO 2 nanoparticles at the same concentration as drug carrier showed no cytotoxicity toward HEK293 cells (Fig. S2 †) , which differs from MSN, indicative of its better biocompatibility than MSN. Higher releasing efficiency of DOX from DOX@PNiPAM@SiO 2 particles taken up by MCF-7 cells might have contributed to the enhanced cytotoxicity of DOX@PNiPAM/AA@SiO 2 . The endocytosis of DOX loaded MSN and PNiPAM/AA@SiO 2 was evaluated by ow cytometry analysis aer incubation for 1 h, 4 h and 12 h, respectively. As DOX is a uorophore, the uorescence intensity is proportional to the amount of DOX in MCF-7 cells. It could be seen from Fig. 8b that the cells without any treatment showed only autouorescence. The uorescence intensity of DOX@MSN and DOX@PNiPAM/AA@SiO 2 increased with the prolonging cultivation time. Although the DOX concentration and cell incubation time were the same, the uorescence intensity of DOX loaded by PNiPAM/AA@SiO 2 was higher than that of DOX loaded by MSN at each time point, respectively. The ow cytometry results indicated that the DOX concentration loaded into the cells by PNiPAM/AA@SiO 2 was higher than that of DOX loaded by MSN, which was in agreement with the result of cellular toxicity.
To verify the pH responsive release behavior of DOX@PNi-PAM/AA@SiO 2 in cells, the intracellular DOX distribution was analyzed by using DOX auto-uorescence aer incubation for 1 or 4 h. Lysotracker Green, a specic probe for acidic compartments, was used to conrm the lysosome colocation of DOX@PNiPAM/AA@SiO 2 . In the group of cells treated with DOX@PNiPAM/AA@SiO 2 , partial DOX gathered in the lysosomes, the uorescence of which overlapped with that of the Lysotracker, and partial DOX dispersed in cytoplasm, surrounding the lysosomes, as shown in Fig. 9a and b . In distinct contrast, in DOX@MSN treatment the red uorescence of DOX was much weaker and mainly colocalized with that of the Lysotracker, and DOX uorescence in cytoplasm was barely visible (Fig. 9c and d) . This experiment further proved that PNiPAM/AA@SiO 2 outperformed MSN in drug release at cellular level.
The difference in cytotoxicity of DOX@PNiPAM/AA@SiO 2 and DOX@MSN might be related to the following two factors. Superior dispersity of PNiPAM/AA@SiO 2 results in the size of the nanoparticles in solution being smaller than that of MSN, which makes it easier for the former to enter cells.
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Furthermore, DOX@PNiPAM/AA@SiO 2 particles have higher drug releasing efficiency in the acidic intracellular microenvironment than DOX@MSN.
Conclusions
In summary, PNiPAM/AA@SiO 2 nanoparticles with good dispersity and the ability to be modied were fabricated through self-assembly of PNiPAM/AA particles and TEOS in water. Many gaps were observed in the aggregated silica shell by TEM. The drug of doxorubicin not only could be loaded into the DOX@PNiPAM/AA@SiO 2 nanoparticles at lower temperature and encapsulated inside PNiPAM@SiO 2 particles by a silica shell at 37 C and neutral pH, but also could be released quickly from the nanoparticles at pH 5.0. 
